| 000 | 01262 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250517024354.0 | ||
| 264 | 0 | _c20151001 | |
| 008 | 201510s 0 0 eng d | ||
| 022 | _a1468-2060 | ||
| 024 | 7 |
_a10.1136/annrheumdis-2015-207543 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Der-Yuan | |
| 245 | 0 | 0 |
_aResponse to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al. _h[electronic resource] |
| 260 |
_bAnnals of the rheumatic diseases _cAug 2015 |
||
| 300 |
_ae43 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Comment | ||
| 650 | 0 | 4 |
_aAntibodies _xblood |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xblood |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 700 | 1 | _aChen, Yi-Ming | |
| 773 | 0 |
_tAnnals of the rheumatic diseases _gvol. 74 _gno. 8 _gp. e43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/annrheumdis-2015-207543 _zAvailable from publisher's website |
| 999 |
_c24773018 _d24773018 |
||